Team Health guidance looks conservative, says RBC Capital RBC Capital believes that Team Health reported "decent" Q4 results, and the firm expects investors to view the results positively. The firm keeps an Outperform rating on the shares.
Team Health may be range bound in near-term after IPC deal, says Stephens Stephens analyst Dana Hambly noted that Team Health's acquisition of IPC Healthcare has not been generally well received by investors and he expects shares to be range bound as investors take a "wait and see" approach regarding the deal. However, he expects early evidence of the deal rationale to show in results in 2H16 and maintains an Overweight rating on Team Health shares. To account for the deal, Hambly lowered his price target on Team Health to $66 from $73.